Clinical implications of the detection of circulating tumor cells in breast cancer patients

Biomarkers in Medicine

Volumn 6, Issue 1, 2012, Pages 109-118

  Banys, Malgorzata ^a,b   Hartkopf, Andreas D ^a   Krawczyk, Natalia ^a   Becker, Sven ^a   Fehm, Tanja ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Marienkrankenhaus Hamburg ^*  (Germany)

Author keywords

biomarker; breast cancer; circulating tumor cell; disseminated tumor cell; prognosis

Indexed keywords

BEVACIZUMAB; TRASTUZUMAB;

BONE MARROW METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; HUMAN; IMMUNOCYTOCHEMISTRY; OVERALL SURVIVAL; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REVIEW; TREATMENT DURATION;

BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CELL SEPARATION; HUMANS; NEOPLASTIC CELLS, CIRCULATING; TREATMENT OUTCOME;

EID: 84856611960     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.106     Document Type: Review

References (63)

1. Ashworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust. Med. J. 14, 146-149 (1869).
2. Paget S. The distribution of secondary growths in cancer of the breast: 1989. Cancer Metastasis Rev. 8(2), 98-101 (1989).
3. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004). (Pubitemid 39095313)
4. Rack BK, Schindlbeck C, Andergassen U, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. Presented at: Clinical Science Symposium, Circulating Tumor Cells in Breast Cancer: Where are We? ASCO Annual Meeting 2010. Chicago, IL, USA, 4-8 June 2010 (Abstract 1003).
5. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 11(4), R59 (2009).
6. Fehm T, Solomayer EF, Meng S, et al. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7(2), 171-185 (2005). (Pubitemid 40872753)
7. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(7), 1420-1430 (2005).
8. Demel U, Tilz GP, Foeldes-Papp Z, Gutierrez B, Albert WH, Bocher O. Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. J. Exp. Clin. Cancer Res. 23(3), 465-468 (2004). (Pubitemid 39490631)
9. Lankiewicz S, Rivero BG, Bocher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol. Biotechnol. 34(1), 15-27 (2006). (Pubitemid 44337216)
10. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J. Clin. 55(1), 31-44, quiz 55-56 (2005). (Pubitemid 40310186)
11. Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res. Treat. 106(2), 239-243 (2007). (Pubitemid 350045008)
12. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103(5), 884-891 (2005). (Pubitemid 40270064)
13. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16(9), 2634-2645 (2010).
14. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a Phase II randomized trial. Clin. Cancer Res. 14(21), 7004-7010 (2008).
15. Molloy TJ, Bosma AJ, Baumbusch LO, et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 13(3), R61 (2011).
16. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 24(23), 3756-3762 (2006). (Pubitemid 46622314)
17. Solomayer EF, Becker S, Pergola-Becker G, et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res. Treat. 98(2), 179-184 (2006). (Pubitemid 44050767)
18. Banys M, Krawczyk N, Becker S, et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res. Treat. doi:10.1007/s10549-011-1569-0 (2011) (Epub ahead of print).
19. Krawczyk N, Banys M, Neubauer H, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10), 4019-4024 (2009).
20. Fehm T, Krawczyk N, Solomayer EF, et al. ERa-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 10(5), R76 (2008).
21. Aktas B, Muller V, Tewes M, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol. Oncol. 122(2), 356-360 (2011).
22. Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad. Sci. USA 101(25), 9393-9398 (2004). (Pubitemid 38812885)
23. Jückstock J, Rack B, Schindlbeck C, et al. Treatment with trastuzumab in recurrence free patients with early breast cancer and persistent disseminated tumor cells (DTC) in bone marrow. Presented at: The 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 10-14 December 2008.
24. Rack B, Juckstock J, Gunthner-Biller M, et al. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch. Gynecol. Obstet. doi:10.1007/s00404-011-1954-2 (2011) (Epub ahead of print).
25. Bozionellou V, Mavroudis D, Perraki M, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10(24), 8185-8194 (2004). (Pubitemid 40053377)
26. Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57(2), 271-280 (2008). (Pubitemid 350159915)
27. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12(14 Pt 1), 4218-4224 (2006).
28. Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 13(3), R67 (2011).
29. Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. doi:10.1093/annonc/mdr263 (2011) (Epub ahead of print).
30. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403-6409 (2006). (Pubitemid 44799711)
31. Ignatiadis M, Perraki M, Apostolaki S, et al. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin. Breast Cancer 7(11), 883-889 (2007).
32. Melcher CA, Janni W, Ortmann U, et al. DETECT III - a multicenter, randomized, Phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. Presented at: San Antonio Breast Cancer Symposium 2011. Henry B Gonzalez Convention Center, TX, USA, 6-10 December 2011 (Abstract OT1-02-06).
33. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res. Treat. 41(2), 177-185 (1996). (Pubitemid 26360147)
34. Pocock SJ, Gore SM, Kerr GR. Long-term survival analysis: the curability of breast cancer. Stat. Med. 1(2), 93-104 (1982). (Pubitemid 13146127)
35. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J. Natl Cancer Inst. 91(1), 80-85 (1999). (Pubitemid 29042447)
36. Krag DN, Ashikaga T, Moss TJ, et al. Breast cancer cells in the blood: a pilot study. Breast J. 5(6), 354-358 (1999).
37. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10(24), 8152-8162 (2004). (Pubitemid 40053373)
38. Fehm T, Becker S, Becker-Pergola G, et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res. 8(5), R60 (2006).
39. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334), 683-689 (2002). (Pubitemid 35232337)
40. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353(8), 793-802 (2005). (Pubitemid 41215488)
41. Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 10(4), 1392-1400 (2004). (Pubitemid 38365234)
42. Schoenfeld A, Kruger KH, Gomm J, et al. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur. J. Cancer 33(6), 854-861 (1997). (Pubitemid 27287035)
43. Ismail MS, Wynendaele W, Aerts JL, et al. Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin. Cancer Res. 10(1 Pt 1), 196-201 (2004). (Pubitemid 38114180)
44. Muller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 11(10), 3678-3685 (2005). (Pubitemid 40685584)
45. Stathopoulou A, Mavroudis D, Perraki M, et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 23(2C), 1883-1890 (2003). (Pubitemid 36750862)
46. Rack B, Schindlbeck C, Andergassen U, et al. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients. Presented at: The 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
47. Nieto Y, Franklin WA, Jones RB, et al. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol. Blood Marrow Transplant. 10(6), 415-425 (2004). (Pubitemid 38647290)
48. Zach O, Kasparu H, Wagner H, Krieger O, Lutz D. Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med. Austriaca Suppl. 59, 32-34 (2002).
49. Daskalaki A, Agelaki S, Perraki M, et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br. J. Cancer 101(4), 589-597 (2009).
50. Ntoulia M, Stathopoulou A, Ignatiadis M, et al. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin. Biochem. 39(9), 879-887 (2006). (Pubitemid 44363084)
51. Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br. J. Cancer 94(5), 672-680 (2006). (Pubitemid 43361898)
52. Bidard FC, Mathiot C, Delaloge S, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 21(4), 729-733 (2010).
53. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20(16), 3404-3412 (2002).
54. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 113(9), 2422-2430 (2008).
55. Nakamura S, Yagata H, Ohno S, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 17(3), 199-204 (2010).
56. Reinholz MM, Kitzmann KA, Tenner K, et al. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, n0234/336/436/437. Clin. Cancer Res. 17(22), 7183-7193 (2011).
57. Nole F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann. Oncol. 19(5), 891-897 (2008). (Pubitemid 351627303)
58. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27(31), 5153-5159 (2009).
59. Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 115(3), 581-590 (2009).
60. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann. Oncol. 19(3), 496-500 (2008). (Pubitemid 351325670)
61. DETECT multicenter study. www.detect-study.de
62. German trial: GeparQuattro. www.germanbreastgroup.de/geparquattro
63. German SUCCESS trial. www.success-studie.de